Home » Novartis Receives European Approval for Onbrez for COPD
Novartis Receives European Approval for Onbrez for COPD
Thursday, Novartis AG ADS, a Swiss drug maker, said that the European Commission has approved its lead compound Onbrez Breezhaler in both 150 mcg and 300
mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease
or COPD.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May